Breaking News Instant updates and real-time market news.

JPM

JPMorgan

$93.84

-0.28 (-0.30%)

, PNC

PNC Financial

$132.62

-0.905 (-0.68%)

10:20
09/26/17
09/26
10:20
09/26/17
10:20

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) and PNC Financial (PNC) were downgraded to Hold from Buy at Deutsche Bank. 2. Aflac (AFL) downgraded to Sell from Neutral at Citi with analyst Suneet Kamath saying the company is at an inflection point as Aflac Japan is too large to show meaningful growth and Aflac U.S. is "too small to move the growth needle." 3. Cardtronics (CATM) downgraded to Market Perform from Outperform at William Blair with analyst Robert Napoli citing the changes in the Australian market. 4. Cheesecake Factory (CAKE), Shake Shack (SHAK), and Habit Restaurants (HABT) were downgraded to Neutral from Outperform at Wedbush. 5. Genocea (GNCA) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying his visibility and confidence "remains admittedly low" after the company shelved GEN-003 and said it will shift focus on immuno-oncology and the development of neoantigen cancer vaccines. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

JPM

JPMorgan

$93.84

-0.28 (-0.30%)

PNC

PNC Financial

$132.62

-0.905 (-0.68%)

AFL

Aflac

$83.23

-1.03 (-1.22%)

CATM

Cardtronics

$26.10

-3.17 (-10.83%)

CAKE

Cheesecake Factory

$41.60

0.08 (0.19%)

SHAK

Shake Shack

$31.60

-2.015 (-6.00%)

HABT

Habit Restaurants

GNCA

Genocea

$5.33

0.04 (0.76%)

  • 26

    Sep

  • 28

    Sep

  • 02

    Oct

  • 12

    Oct

  • 13

    Oct

  • 22

    Oct

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

JPM JPMorgan
$93.84

-0.28 (-0.30%)

07/11/17
BARD
07/11/17
NO CHANGE
BARD
Big bank set-up not great, would sell into extended rally, says Baird
Baird analyst David George does not see a great set-up for money-center banks heading into Q2 earnings. He said the trade looks crowded and he would be a seller into an extended rally. George said the risk/reward is less attractive following the sector's most recent rally as economic growth remains muted and the pace of NIM expansion may slow. George believes the biggest potential catalyst would be a gradual steepening of the yield curve and pick-up on loan growth.
09/26/17
DBAB
09/26/17
DOWNGRADE
Target $136
DBAB
Hold
PNC Financial downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Matt O'Connor downgraded PNC Financial (PNC) to Hold as he seeks to lessen exposure to traditional banks. The analyst sees net interest income growth slowing and credit costs inching up as the Fed raises short rates and the yield curve flattens. He believes a number of positives are priced into PNC shares. O'Connor upped his price target for the stock to $136 from $130. The analyst continues to prefer banks with a "turnaround angle," like Goldman Sachs (GS) and Wells Fargo (WFC), and remains positive on capital markets businesses like Morgan Stanley (MS). O'Connor this morning also downgraded JPMorgan (JPM) to Hold.
09/26/17
DBAB
09/26/17
DOWNGRADE
Target $96
DBAB
Hold
JPMorgan downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Matt O'Connor downgraded JPMorgan to Hold as he seeks to lessen exposure to traditional banks. The analyst sees net interest income growth slowing and credit costs inching up as the Fed raises short rates and the yield curve flattens. He believes further meaningful outperformance of JPMorgan shares will be harder amid increased competition within investment banking and trading as well as slowing loan growth. The analyst raised his price target for the shares to $96 from $90. The bank closed yesterday down 71c to $94.12.
08/09/17
WELS
08/09/17
INITIATION
Target $110
WELS
Outperform
JPMorgan resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage JPMorgan with an Outperform rating and $110 price target.
PNC PNC Financial
$132.62

-0.905 (-0.68%)

07/17/17
RAFF
07/17/17
UPGRADE
RAFF
Buy
PNC Financial upgraded to Buy from Hold at Rafferty Capital
07/17/17
FBCO
07/17/17
NO CHANGE
Target $126
FBCO
Neutral
PNC Financial price target raised to $126 from $114 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke raised her price target for PNC Financial to $126 from $114 after the company reported Q2 EPS "solidly" above consensus. The analyst reiterates a Neutral rating on the shares.
08/09/17
WELS
08/09/17
INITIATION
Target $119
WELS
Market Perform
PNC Financial resumed with a Market Perform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of PNC Financial with a Market Perform rating and $119 price target.
AFL Aflac
$83.23

-1.03 (-1.22%)

09/26/17
SBSH
09/26/17
DOWNGRADE
Target $79
SBSH
Sell
Aflac downgraded to Sell from Neutral at Citi
Citi analyst Suneet Kamath downgraded Aflac to Sell and cut his price target for the shares to $77 from $82. The company is at an inflection point as Aflac Japan is too large to show meaningful growth and Aflac U.S. is "too small to move the growth needle," Kamath tells investors in a research note titled "Growth is Hard to Find, Other than in AFL's Valuation Multiples." The analyst estimates the annual earnings growth going forward at 1% and 5%, respectively, which he says is well below peer levels and "at odds" with the stock's valuation.
06/09/17
JPMS
06/09/17
NO CHANGE
JPMS
Overweight
Aflac president resignation a surprise, says JPMorgan
JPMorgan analyst Jimmy Bhullar views the resignation of Paul Amos II, President of Aflac and son of CEO Dan Amos, as a surprise. Paul Amos was widely regarded as the leading candidate to succeed Dan Amos as CEO, Bhullar tells investors in a research note. The analyst also finds it "odd" that Amos II is receiving a $3.4M payment as part of the resignation, which he notes equates to 30 months of base salary and an annual incentive award for fiscal 2017. Bhullar, however, does not anticipate a major near-term disruption in Aflac's operations or a change in strategy, despite speculation of a separation of the Japan and U.S. divisions. He also now believes CEO Amos is unlikely to retire in the near term, which the analyst views as a positive. Bhullar has an Overweight rating on Aflac and says the stock remains his top pick for the life insurance sector.
09/08/17
09/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to Neutral on declining US beverage sales at Credit Suisse with analyst Laurent Grandet saying risk/reward is "balanced" following an 11% share appreciation over the past year, especially with US beverage sales struggling year-to-date. 2. Chipotle (CMG) downgraded to Underperform from Market Perform at Cowen with analyst Andrew Charles citing proprietary survey data that indicates the company's quality and value perceptions remain at trough levels, leading him to believe the sales recovery will continue to trail investor expectations. 3. Aflac (AFL) downgraded to Underperform from Neutral at BofA/Merrill with analyst Seth Weiss citing relative valuation. 4. Kroger (KR) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh citing the company's second quarter results. 5. Rice Energy (RICE) downgraded to Neutral from Buy at Goldman Sachs with analyst Brian Singer citing valuation following recent outperformance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
BOFA
09/08/17
DOWNGRADE
Target $83
BOFA
Underperform
Aflac downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill analyst Seth Weiss downgraded Aflac to Underperform with a $83 price target citing relative valuation.
CATM Cardtronics
$26.10

-3.17 (-10.83%)

06/22/17
RHCO
06/22/17
NO CHANGE
RHCO
Cardtronics should be bought on weakness, says SunTrust
SunTrust analyst Andrew Jeffrey recommends buying Cardtronics on weakness. The analyst thinks that the company remains well-positioned to take share in the ATM market, and he thinks that it is facing near-term headwinds, not structural weaknesses.
09/25/17
WBLR
09/25/17
DOWNGRADE
WBLR
Market Perform
Cardtronics downgraded to Market Perform from Outperform at William Blair
William Blair analyst Robert Napoli downgraded Cardtronics to Market Perform citing the changes in the Australian market. Shares of Cardtronics fell 11% today to $3.17 after the four largest banks in Australia eliminated its surcharges for using ATMs. The company admitted in a regulatory filing this morning that the introduction of free-to-use ATMs may adversely impact its revenue in the near term.
09/25/17
JPMS
09/25/17
NO CHANGE
JPMS
Neutral
Cardtronics selloff feels like an overreaction, says JPMorgan
JPMorgan analyst Reginald Smith says today's selloff in shares of Cardtronics "feels like an overreaction fundamentally," but not unexpected after Australia's four largest banks eliminated ATM surcharges. The introduction of free-to-use ATMs in Australia will likely have negative consequences for banks and independent ATM operators like Cardtronics, Smith tells investors in a research note. He keeps a Neutral rating on the shares.
09/25/17
RHCO
09/25/17
NO CHANGE
Target $40
RHCO
Buy
Cardtronics selloff 'reasonable' on Australia news, says SunTrust
SunTrust analyst Andrew Jeffrey views today's selloff in shares of Cardtronics as "reasonable" given the negative news on surcharging from Australia. The analyst estimates the net adverse effect of Australian surcharge elimination at about $15M in 2018, indicating a 10% share pullback. Jeffrey says his secular outsourcing thesis remains intact, however, and he reiterates a Buy rating on Cardtronics with a $40 price target. The analyst favors the stock over the long term but sees a lack of near-term catalysts. Cardtronics is afternoon trading is down 11% to $25.97.
CAKE Cheesecake Factory
$41.60

0.08 (0.19%)

09/26/17
09/26/17
DOWNGRADE
Target $44

Neutral
Cheesecake Factory downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Nick Setyan downgraded Cheesecake Factory to Neutral from Outperform saying he expects continued pressure on casual dining comp trends, creating risk to current margin expectations and guidance. The analyst also lowered his price target on the shares to $44 from $52.
07/12/17
NOMU
07/12/17
INITIATION
Target $50
NOMU
Neutral
Cheesecake Factory initiated with a Neutral at Nomura Instinet
Nomura Instinet analyst Mark Kalinowski initiated Cheesecake Factory with a Hold and a $50 price target saying sahres are trading near fair value.
09/26/17
WEDB
09/26/17
DOWNGRADE
WEDB
Neutral
Cheesecake Factory downgraded to Neutral from Outperform at Wedbush
08/30/17
08/30/17
NO CHANGE

Wedbush estimates Harvey's impact on restaurant chains
Wedbush analyst Nick Setyan says that Jack in the Box (JACK), Fiesta Restaurant (FRGI), Chuy's (CHUY), Cheesecake Factory (CAKE), and BJ's Restaurants (BJRI0 have the most exposure to Hurricane Harvey among restaurant owners. The analyst estimates that 20% of restaurants owned by Jack in the Box are in the area and 27% of Fiesta's Taco Cabana restaurants are in Houston, while 9% of Chuy's restaurants, 3% of Cheesecake's units, and 2% of BJ's units are in the area,. The analyst estimates that Jack in the Box's EPS loss could be as high as .007c per day, while Fiesta's EPS loss may be as high as .005c per day, and Chuy could lose .004c of EPS per day. Finally, Cheesecake and BJ's could lose u[p to .002c of EPS per day, the analyst stated.
SHAK Shake Shack
$31.60

-2.015 (-6.00%)

09/26/17
09/26/17
DOWNGRADE
Target $36

Neutral
Shake Shack downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Nick Setyan downgraded Shake Shack to Neutral from Outperform saying he expects a continuation of muted fast casual trends to be exacerbated by near to medium-term cannibalization from new units, creating risk to current margin expectations and guidance. The analyst also lowered his price target on the shares to $36 from $40.
08/04/17
PIPR
08/04/17
NO CHANGE
Target $44
PIPR
Overweight
Shake Shack reported 'strong' Q2 results, says Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan says Shake Shack reported "strong" Q2 results with sales and earnings coming in ahead of consensus expectations. Trends are "generally well positioned" given an ongoing focus around accelerated development even though comp guidance for FY17 was trimmed, Regan tells investors in a post-earnings research note. She keeps an Overweight rating on Shake Shack with a $44 price target.
06/27/17
GSCO
06/27/17
NO CHANGE
Target $29
GSCO
Sell
Shake Shack Q2 comps may be impacted by weather at Goldman Sachs
Goldman analyst Karen Holthouse sees potential headwinds to Q2 comps due to the increased number precipitation days in the quarter, 14 days versus the previous year of 8 days. The analyst maintains her below consensus comp estimate of down 2.5% versus consensus of up .4% and reiterates her Sell rating and $29 price target.
09/26/17
WEDB
09/26/17
DOWNGRADE
WEDB
Neutral
Shake Shack downgraded to Neutral from Outperform at Wedbush
HABT Habit Restaurants

09/26/17
WEDB
09/26/17
DOWNGRADE
WEDB
Neutral
Habit Restaurants downgraded to Neutral from Outperform at Wedbush
03/23/17
PIPR
03/23/17
NO CHANGE
Target $20
PIPR
Overweight
Piper Jaffray says buy Habit Restaurants on relative valuation
Piper Jaffray analyst Nicole Miller Regan says Habit Restaurants is a buy given an attractive relative valuation versus other fast casual growth names. The concept itself remains compelling in terms of unit-level economics and continued execution, Regan tells investors in a research note. She reiterates an Overweight rating on Habit shares with a $20 price target.
09/26/17
09/26/17
DOWNGRADE
Target $14

Neutral
Habit Restaurants downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Nick Setyan downgraded Habit Restaurants (HABT) to Neutral from Outperform saying he expects continued positive trends in Restaurant Brands (QSR) to pressure comp trends at the former, creating risk to current margin expectations and guidance. The analyst also lowered his price target on Habit's shares to $14 from $19.
08/03/17
COWN
08/03/17
DOWNGRADE
COWN
Market Perform
Habit Restaurants downgraded to Market Perform from Outperform at Cowen
GNCA Genocea
$5.33

0.04 (0.76%)

07/25/17
07/25/17
UPGRADE
Target $12

Buy
Genocea upgraded to Buy at Needham
As previously reported, Needham analyst Alan Carr upgraded Genocea to Buy from Hold, with a $12 price target, after the company announced data from GEN-003 Phase 2b trial in HSV2 demonstrating durable efficacy through 12 months, and as he believes there is a "feasible" independent path to market. The analyst thinks GEN-003 is likely to be differentiated and convenient option with public health benefits.
07/25/17
STFL
07/25/17
NO CHANGE
STFL
Genocea data positive, says Stifel
Stifel analyst Stephen D. Willey says that Phase 2b data showing that Genocea's f GEN-003 achieved its primary endpoint in treating genital herpes is positive. The analyst says any clarity into new funding for a Phase 3 development program "should help re-rate the stock to a valuation which more appropriately reflects the longer-term market opportunity." He keeps a $15 price target and a Buy rating on the stock.
09/26/17
09/26/17
DOWNGRADE
Target $2.5

Hold
Genocea downgraded to Hold after strategy shift at Stifel
As previously reported, Stifel analyst Stephen Willey downgraded Genocea to Hold from Buy, saying his visibility and confidence "remains admittedly low" after the company shelved GEN-003 and said it will shift focus on immuno-oncology and the development of neoantigen cancer vaccines. He reduced his price target on Genocea shares to $2.50 from $15.
09/25/17
STFL
09/25/17
DOWNGRADE
STFL
Hold
Genocea downgraded to Hold from Buy at Stifel

TODAY'S FREE FLY STORIES

GNRC

Generac

$50.49

-0.4 (-0.79%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Recommendations
Generac analyst commentary  »

Generac estimates raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

ADP

ADP

$113.72

-0.86 (-0.75%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Periodicals
Ackman increases pressure on ADP over tech development, WSJ reports »

Activist investor and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

PRKR

ParkerVision

$1.50

-0.06 (-3.85%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Hot Stocks
ParkerVision enters common stock purchase agreement with Aspire Capital »

ParkerVision announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRO

GoPro

$9.23

0.15 (1.65%)

07:19
10/18/17
10/18
07:19
10/18/17
07:19
Technical Analysis
Technical View: GoPro trades higher, analyst action »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NAVI

Navient

$12.20

0.47 (4.01%)

07:17
10/18/17
10/18
07:17
10/18/17
07:17
Hot Stocks
Navient sees adding over $1B of education refinance loans in FY17 »

Including the planned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Conference/Events
Commodity Futures Trading Commission Commissioners to speak at Expo »

Brian Quintenz and Rostin…

FGEN

FibroGen

$55.30

0.8 (1.47%)

, AZN

AstraZeneca

$34.78

0.13 (0.38%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Hot Stocks
FibroGen announces CFDA acceptance of roxadustat NDA »

FibroGen (FGEN) and its…

FGEN

FibroGen

$55.30

0.8 (1.47%)

AZN

AstraZeneca

$34.78

0.13 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 08

    Nov

  • 09

    Nov

CMG

Chipotle

$329.30

8.91 (2.78%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Technical Analysis
Technical View: Chipotle falls, analyst actions »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

UNH

UnitedHealth

$203.89

10.69 (5.53%)

, AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

07:16
10/18/17
10/18
07:16
10/18/17
07:16
Recommendations
UnitedHealth, Amazon.com analyst commentary  »

UnitedHealth price target…

UNH

UnitedHealth

$203.89

10.69 (5.53%)

AMZN

Amazon.com

$1,009.13

2.79 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 18

    Mar

AAN

Aaron's

$41.55

0.01 (0.02%)

07:15
10/18/17
10/18
07:15
10/18/17
07:15
Initiation
Aaron's initiated  »

Aaron's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

, FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Conference/Events
FDIC to hold a committee meeting »

The FDIC's Advisory…

BMTC

Bryn Mawr Bank

$44.50

-0.1 (-0.22%)

FCF

First Commonwealth

$13.94

-0.26 (-1.83%)

ONB

Old National Bancorp

$18.40

-0.05 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 25

    Oct

  • 06

    Nov

HCC

Warrior Met Coal

$24.04

0.51 (2.17%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Downgrade
Warrior Met Coal rating change  »

Warrior Met Coal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

, UNH

UnitedHealth

$203.89

10.69 (5.53%)

07:13
10/18/17
10/18
07:13
10/18/17
07:13
Periodicals
Health insurers prepare for enrollment drop amid ACA uncertainty, WSJ says »

As enrollment for 2018…

MOH

Molina Healthcare

$61.54

1.68 (2.81%)

UNH

UnitedHealth

$203.89

10.69 (5.53%)

CNC

Centene

$93.80

2.88 (3.17%)

WCG

WellCare

$174.03

6.11 (3.64%)

CI

Cigna

$187.20

2.21 (1.19%)

ANTM

Anthem

$187.26

3.5 (1.90%)

HNT

Health Net

HUM

Humana

$240.43

3.26 (1.37%)

AET

Aetna

$155.90

4.46 (2.95%)

EHTH

eHealth

$23.79

-0.61 (-2.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 31

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 14

    Dec

IBM

IBM

$146.54

-0.29 (-0.20%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Recommendations
IBM analyst commentary  »

IBM reported 'best…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

NVO

Novo Nordisk

$49.31

-0.01 (-0.02%)

07:12
10/18/17
10/18
07:12
10/18/17
07:12
Conference/Events
FDA Endocrinologic & Metabolic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$355.75

5.15 (1.47%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Periodicals
Tesla employees claim dismissals not performance related, CNBC reports »

Tesla is trying to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ATTU

Attunity

$6.90

0.12 (1.77%)

07:11
10/18/17
10/18
07:11
10/18/17
07:11
Hot Stocks
Attunity's Replicate adopted by large health insurance provider »

Attunity announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

MYGN

Myriad Genetics

$35.84

-0.26 (-0.72%)

07:10
10/18/17
10/18
07:10
10/18/17
07:10
Hot Stocks
Myriad Genetics BRACAnalysis CDx sPMA by FDA for review »

Myriad Genetics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

MAIN

Main Street

$40.07

-0.1 (-0.25%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Main Street announces semi-annual supplemental cash dividend of 27.5c per share »

Main Street Capital is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

JNJ

Johnson & Johnson

$140.79

4.67 (3.43%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Recommendations
Johnson & Johnson analyst commentary  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

IONS

Ionis Pharmaceuticals

$63.85

2.7 (4.42%)

07:09
10/18/17
10/18
07:09
10/18/17
07:09
Hot Stocks
Ionis collaborates with Seventh Sense Biosystems in blood collection device »

Ionis Pharmaceuticals has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 26

    Oct

LRCX

Lam Research

$194.55

2.19 (1.14%)

07:08
10/18/17
10/18
07:08
10/18/17
07:08
Recommendations
Lam Research analyst commentary  »

Lam Research price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMRN

Immuron

$5.03

0.1 (2.03%)

07:06
10/18/17
10/18
07:06
10/18/17
07:06
Initiation
Immuron initiated  »

Immuron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

, RHHBY

Roche

$31.45

0.27 (0.87%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
BioLineRx: Genentech initiates Phase 1b/2 trial for BL-8040 »

BioLineRx (BLRX)…

BLRX

BioLineRx

$1.09

-0.065 (-5.63%)

RHHBY

Roche

$31.45

0.27 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

CEVA

CEVA

$45.40

0.1 (0.22%)

07:05
10/18/17
10/18
07:05
10/18/17
07:05
Hot Stocks
CEVA and Brodmann17 partner for deep learning in edge devices »

CEVA and Broadmann17, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.